Canaccord analyst Michelle Gilson noted ChemoCentrx’s partner Vifor announced they increased their ownership stake in the company and she views it as a vote of confidence in its rare renal franchise. The analyst said the weakness overlooks the avacopan strong clinical data for AAV and she expects a broad uptake of the drug if Phase 3 is successful. Gilson reiterated her Buy rating and $18 price target on ChemoCentryx shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.